PROSTANOIDS IN COLON CANCER--CELL/MOLECULAR MECHANISMS

前列腺素在结肠癌中的作用——细胞/分子机制

基本信息

  • 批准号:
    2517650
  • 负责人:
  • 金额:
    $ 23.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1996
  • 资助国家:
    美国
  • 起止时间:
    1996-09-01 至 2000-08-31
  • 项目状态:
    已结题

项目摘要

Eicosatraenoic acids (mostly arachidonic acid, 20:4,omega-6) are metabolized by many cells to a variety of signalling compounds (eicosanoids) that act locally. This metabolic event occurs in response to a variety of stimuli including hormones and environmental insults, and arachidonate can be channelled through several enzymatic pathways, including prostaglandin endoperoxide synthases (cyclo-oxygenases) to yield ultimately the prostanoids. Evidence suggesting the importance of prostanoids in the cinogenesis of human colonic epithelium include: a) their increased concentration in tumor tissue; b) their ability to decrease tumor proliferation rate in vitro; and c) clinical trials suggesting that drugs with a primary effect of inhibiting cyclo- oxygenases (and therefore prostanoid synthesis) are associated with regression of polyps in pre-malignant conditions as well as in the general population without known predisposing factors. However, little is known of the mechanisms by which these effects occur, nor the ability of normal or transformed epithelial cells to use a particular signalling pathway after binding a prostanoid via a specific receptor. Several recent advances now allow these issues to be addressed: 1) Procurement of sequence information/cloning of receptors for prostanoids EP2, EP3, EP4, IP, FP and TP; 2) A cDNA clone for a second (inducible) cyclo- oxygenase with potential importance in the intestinal mucosa, in addition to cyclo-oxygenase 1 already available; 3) Sequence information on a prostaglandin transporter for the intestinal epithelial cell, thought to be important in terminating cellular effects of prostanoids. All probes available can be used with quantitative techniques (nuclease protection assays) as well as for methodology localizing macromolecules in complex tissues (in situ hybridization). The aim of this proposal, then, is to determine mechanisms whereby responses to prostanoids by epithelial cells of the intestinal mucosa are regulated, as influenced by the array of receptors for prostanoids which epithelial cells express inherently or the level of prostanoid-generated cyclo-oxygenase enzyme, and how this contributes to or inhibits growth of intestinal colonic epithelial cell tumors. Specifically, we propose to test the hypotheses that: (1) Colonic epithelial cells "in transition" (to adenocarcinoma) respond to prostanoids in a unique way, compared with normal colonic epithelium, due to their expression of a novel set of prostanoid receptors/signalling proteins: (2) Continuing signals exist for up-regulation of cyclo-oxygenase-2 (COX- 2) in colonic mucosal epithelium and in selected cells of the lamina propria; that COX-2 in mucosa is inhibited by certain (of seven) NSAIDS proposed for study; and that the cell distribution/regulation of COX will differ considerably between subjects with epithelium in transition to adenocarcinoma and those with normal epithelium (no current or past polyps). Epithelial cells "in transition" will be from the colon of both an animal model (azoxymethane-treated rats) as well as humans with known tumor predisposition (familial adenomatous polyposis, history of multiple recurrent polyps), and our analyses will use molecular probes developed and present in our laboratory (DNA's coding for known members of the prostanoid receptor family as well as for COX-1 and 2); individual prostanoid receptor-specific immunoglobulin, and in situ techniques (for hybridization and immunocytochemistry).
二十碳四烯酸(主要是花生四烯酸,20:4,ω -6)是

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James K. Roche其他文献

Viral DNA in Inflammatory Bowel Disease: CMV-bearing cells as a target for immune-mediated enterocytolysis
  • DOI:
    10.1016/s0016-5085(77)80077-2
  • 发表时间:
    1977-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    James K. Roche;E-S. Huang
  • 通讯作者:
    E-S. Huang
Facilities for open heart surgery in the United States: Distribution, utilization and cost
  • DOI:
    10.1016/s0002-9149(73)80125-0
  • 发表时间:
    1973-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    James K. Roche;James M. Stengle
  • 通讯作者:
    James M. Stengle
Rabbit antibodies to ovine-submaxillary mucin. Detection, specificity and cross-reactivity.
兔抗绵羊颌下粘蛋白抗体。
  • DOI:
    10.1016/0161-5890(78)90096-2
  • 发表时间:
    1978
  • 期刊:
  • 影响因子:
    0
  • 作者:
    James K. Roche;Eugene D. Day;Hoyle D. Hill
  • 通讯作者:
    Hoyle D. Hill
Prostanoids in human colonic mucosa: Effects of inflammation on PGE<sub>2</sub> receptor expression
  • DOI:
    10.1016/s0016-5085(00)85326-3
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    James K. Roche;Rosana Cosme;Darienne Lublin;Vivian Takafuji;Kevin Lynch
  • 通讯作者:
    Kevin Lynch
Chronic Inflammatory Bowel Disease: Absence of Adenovirus DNA as Established by Molecular Hybridization
  • DOI:
    10.1016/s0016-5085(81)80108-4
  • 发表时间:
    1981-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    James K. Roche;William S.M. Wold;Patricia R. Sanders;Jesse K. Mackey;Maurice Green
  • 通讯作者:
    Maurice Green

James K. Roche的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James K. Roche', 18)}}的其他基金

CONTROL OF CYTOKINE RELEASE FROM HUMAN MUCOSAL T CELLS
控制人粘膜 T 细胞释放细胞因子
  • 批准号:
    6198056
  • 财政年份:
    2000
  • 资助金额:
    $ 23.44万
  • 项目类别:
CONTROL OF CYTOKINE RELEASE FROM HUMAN MUCOSAL T CELLS
控制人粘膜 T 细胞释放细胞因子
  • 批准号:
    6374631
  • 财政年份:
    2000
  • 资助金额:
    $ 23.44万
  • 项目类别:
PROSTANOIDS IN COLON CANCER--CELL/MOLECULAR MECHANISMS
前列腺素在结肠癌中的作用——细胞/分子机制
  • 批准号:
    2895352
  • 财政年份:
    1996
  • 资助金额:
    $ 23.44万
  • 项目类别:
PROSTANOIDS IN COLON CANCER--CELL/MOLECULAR MECHANISMS
前列腺素在结肠癌中的作用——细胞/分子机制
  • 批准号:
    2769808
  • 财政年份:
    1996
  • 资助金额:
    $ 23.44万
  • 项目类别:
PROSTANOIDS IN COLON CANCER--CELL/MOLECULAR MECHANISMS
前列腺素在结肠癌中的作用——细胞/分子机制
  • 批准号:
    2112115
  • 财政年份:
    1996
  • 资助金额:
    $ 23.44万
  • 项目类别:
IMMUNE RESPONSES BY GUT-ASSOCIATED LYMPHOID TISSUE
肠道相关淋巴组织的免疫反应
  • 批准号:
    2135838
  • 财政年份:
    1994
  • 资助金额:
    $ 23.44万
  • 项目类别:
IMMUNOBIOLOGY OF TAMARIN COLITIS
狨猴结肠炎的免疫生物学
  • 批准号:
    3243424
  • 财政年份:
    1990
  • 资助金额:
    $ 23.44万
  • 项目类别:
IMMUNOBIOLOGY OF TAMARIN COLITIS
狨猴结肠炎的免疫生物学
  • 批准号:
    3243425
  • 财政年份:
    1990
  • 资助金额:
    $ 23.44万
  • 项目类别:
IMMUNOBIOLOGY OF COLITIS
结肠炎的免疫生物学
  • 批准号:
    2142250
  • 财政年份:
    1990
  • 资助金额:
    $ 23.44万
  • 项目类别:
IMMUNOBIOLOGY OF TAMARIN COLITIS
狨猴结肠炎的免疫生物学
  • 批准号:
    3243422
  • 财政年份:
    1990
  • 资助金额:
    $ 23.44万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 23.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了